PolymorфPharma
Smart nanotechnology for patentable supergenerics
Effective time frame of patent for drug is twice shorter than nominal because of long clinical trial.
Only 10% of prospective drugs, entering clinical trials, get approval of FDA.
We offer pharmaceutical companies to stay on top of nosology of their expiring drug by making its improved and newly patented version that will
• be better than original (more active, less toxic etc)
• require less clinical trial than new drug
Only 10% of prospective drugs, entering clinical trials, get approval of FDA.
We offer pharmaceutical companies to stay on top of nosology of their expiring drug by making its improved and newly patented version that will
• be better than original (more active, less toxic etc)
• require less clinical trial than new drug
We transform drug from stable to metastable form by changing its crystallic matrix and/or molecule conformation, like on this example:
Some international patents for drugs developed with our technology
1. Kristalline Modification des Hydrogenchlorinds des 2-Dymethylaminoathylesters der n-Buty-laminoBenzoesaure, Verfahren zur Herstellung dieser Modifikation und Arzneimittelpraparat zur Anasthesie der Augen auf Ihrer Basis. Europ. Pat. № 0553351, 1991.
2. Crystalline modification of hydrochloride of 2-dimethylaminoethyl ether of N-butylamino benzoic acid, method of obtaining it and pharmaceutical preparation for anesthesia of the eye based there upon. Austral. Pat. № 647824, 1994.
3. Antimicrobial and interferon inducing pharmaceutical compound. Austral. Pat. № 665127, 1993.
4. Crystalline modification of 2,4-dioxo-6-methyl-1,2,3,4-tetrahydropyrimidine, method of obtaining the same and a pharmaceutical preparation based on it. Austral. Pat. № 669511, 1993.
5. Method of Obtaining a Physically stable crystalline ﻻ-modification of para-aminobenzene Sulphanilamide. Austral. Pat. 668458, Int CI.C 07 C 311/39. 1993.
6. Crystalline Modification of 2-dimethylaminoethyl-n-Butylaminobenzoate Hydrochloride. Method for Production thereof and Pharmaceutical Preparation for Anaesthesiia of Eyes, Based thereon. US Pat. № 5403951, 1995.
7. Crystalline Modification of 2-Dimethylaminoethyl-n-Butylaminobenzoate Hydrochloride. Method for Production thereof and Pharmaceutical Preparation for Anaesthesiia of Eyes, Based thereon. US Pat. 5453532, Int.CI. C 07 C 229/10, 1995.
8. Antimicrobial Interferon-Inducing Medicament. US Pat. 5510387, Int.CI. A 61 K 31/18, 1996.
9. Crystalline Modification of 2,4-dioxo-6-methyl-1,2,3,4-tetrahydropyri-midine, method of obtain-ing the same and a pharmaceutical preparation based on it. US Pat. № 5543147, 1996.
10. Crystalline Modification of hydrochloride of 2-dimethylaminoethyl ether of N-butylamino benzoic acid, method of obtaining it and pharmaceutical preparation for anesthesia of the eye based there upon. Japan. Pat. № 2017962, 1996.
11. Modifikation du resean criltallin du chlorhydrure de 2-dimethyl-aminoeth-yl-N-butylaminobenzoate, methode d, obtention et preparation pharmaceutigue pour l anesthesie oculaire ainsi obtenue. Canad. Pat. № 2,091,686, 1997.
12. Modifikation criltalline de la 2,4-dioxo-6-methyl-1,2,3,4-trahydropyrimidine, methode de preparation et preparation medicale a base de cette molecuie. Canad. Pat. № 2,132,417, 1997.
13. Crystalline modification of 2,4-dioxo-6-methyl-1,2,3,4-tetrahydropyrimidine, method of obtaining the same and a pharmaceutical preparation based on its. Japan Pat. № 2624897, 1993.
2. Crystalline modification of hydrochloride of 2-dimethylaminoethyl ether of N-butylamino benzoic acid, method of obtaining it and pharmaceutical preparation for anesthesia of the eye based there upon. Austral. Pat. № 647824, 1994.
3. Antimicrobial and interferon inducing pharmaceutical compound. Austral. Pat. № 665127, 1993.
4. Crystalline modification of 2,4-dioxo-6-methyl-1,2,3,4-tetrahydropyrimidine, method of obtaining the same and a pharmaceutical preparation based on it. Austral. Pat. № 669511, 1993.
5. Method of Obtaining a Physically stable crystalline ﻻ-modification of para-aminobenzene Sulphanilamide. Austral. Pat. 668458, Int CI.C 07 C 311/39. 1993.
6. Crystalline Modification of 2-dimethylaminoethyl-n-Butylaminobenzoate Hydrochloride. Method for Production thereof and Pharmaceutical Preparation for Anaesthesiia of Eyes, Based thereon. US Pat. № 5403951, 1995.
7. Crystalline Modification of 2-Dimethylaminoethyl-n-Butylaminobenzoate Hydrochloride. Method for Production thereof and Pharmaceutical Preparation for Anaesthesiia of Eyes, Based thereon. US Pat. 5453532, Int.CI. C 07 C 229/10, 1995.
8. Antimicrobial Interferon-Inducing Medicament. US Pat. 5510387, Int.CI. A 61 K 31/18, 1996.
9. Crystalline Modification of 2,4-dioxo-6-methyl-1,2,3,4-tetrahydropyri-midine, method of obtain-ing the same and a pharmaceutical preparation based on it. US Pat. № 5543147, 1996.
10. Crystalline Modification of hydrochloride of 2-dimethylaminoethyl ether of N-butylamino benzoic acid, method of obtaining it and pharmaceutical preparation for anesthesia of the eye based there upon. Japan. Pat. № 2017962, 1996.
11. Modifikation du resean criltallin du chlorhydrure de 2-dimethyl-aminoeth-yl-N-butylaminobenzoate, methode d, obtention et preparation pharmaceutigue pour l anesthesie oculaire ainsi obtenue. Canad. Pat. № 2,091,686, 1997.
12. Modifikation criltalline de la 2,4-dioxo-6-methyl-1,2,3,4-trahydropyrimidine, methode de preparation et preparation medicale a base de cette molecuie. Canad. Pat. № 2,132,417, 1997.
13. Crystalline modification of 2,4-dioxo-6-methyl-1,2,3,4-tetrahydropyrimidine, method of obtaining the same and a pharmaceutical preparation based on its. Japan Pat. № 2624897, 1993.
Request your superdrug
Please tell us about your goals / what drug you are interested in and we tell you if we can make it superior
By pressing this button you agree to provide information above. It won't be shared with third parties.
+1 323 620 86 86
+7 495 921 64 32
info@polymorpharma.com
+7 495 921 64 32
info@polymorpharma.com
8A Mozhayskiy Val Street,
Moscow
Moscow